Tools
Stock profile

KAZIA THERAPEUTICS LTD (KZIA)

KZIA · Latest close $5.49 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$5.49
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

KAZIA THERAPEUTICS LTD (KZIA) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions versus the previous quarter. Latest close $5.49 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Leon Cooperman — 1 tracked fund hold KZIA. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Leon Cooperman0.02%50,000NEW Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -60.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

28.802.062024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding36 of 8,857 filers
Long-only filers among them36
Change vs 2026 Q1+13 net · 36 entered · 23 exited
Shares reported, all filers3,639,348
Reported value, all filers$56.3M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY202542.0K AUD
Net income · FY2025-20.7M AUD
Total assets · FY20256.1M AUD
Shares outstanding809,418,734
Market cap (at latest close)$4.4B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jun 30, 2025.

Short interest

Shares short · Oct 15, 20261,308,383
Share of shares outstanding0.16%
Days to cover5.41

Shares short at recent settlements — Jul 31, 2026: 679K · Aug 14, 2026: 559K · Aug 31, 2026: 906K · Sep 15, 2026: 770K · Sep 30, 2026: 1.2M · Oct 15, 2026: 1.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jun 30, 2025.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 70 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jun 30, 2025.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Oct 2, 2026Dauntless Investment Group, LLCSC 13G/A842,3405.4%Sep 25, 2026SEC filing
Aug 19, 2026Chernett JoreySC 13G/A2,339,00919.6%Aug 5, 2026SEC filing
Aug 14, 2026Ikarian Capital, LLCSC 13G/A575,7784.9%Jun 30, 2026SEC filing
Aug 14, 2026Lynwood Capital Management Inc.SC 13G/A264,980,5004.6%Jun 30, 2026SEC filing
May 27, 2026Chernett JoreySC 13G/A2,114,64918.5%May 26, 2026SEC filing
Mar 31, 2026Chernett JoreySC 13G/A1,588,12913.9%Mar 24, 2026SEC filing
Mar 30, 2026Alumni Capital LPSC 13G/A00.0%Jan 30, 2026SEC filing
Feb 20, 2026Chernett JoreySC 13G/A1,412,66212.5%Feb 18, 2026SEC filing
Feb 17, 2026Ikarian Capital, LLCSC 13G580,7545.1%Dec 31, 2025SEC filing
Feb 12, 2026Dauntless Investment Group, LLCSC 13G/A10.0%Dec 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Red Flags

· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)

Key figures

· Late Filings (NT) — Latest event: Oct 31, 2025 · Events in 2 yrs: 2 · Latest form: NT 20-F

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold KZIA — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

No Form 8-K filings for this ticker in the index (Jan 2023 – present).

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on KZIA

One email a week: the week’s new filings and research. Subscribe free

← KYTX  ·  L →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.